Cargando…

Systems-level conservation of the proximal TCR signaling network of mice and humans

We exploited traceable gene tagging in primary human T cells to establish the composition and dynamics of seven canonical TCR-induced protein signaling complexes (signalosomes) using affinity purification coupled with mass spectrometry (AP-MS). It unveiled how the LAT adaptor assembles higher-order...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolas, Philippe, Ollier, Jocelyn, Mori, Daiki, Voisinne, Guillaume, Celis-Gutierrez, Javier, Gregoire, Claude, Perroteau, Jeanne, Vivien, Régine, Camus, Mylène, Burlet-Schiltz, Odile, Gonzalez de Peredo, Anne, Clémenceau, Béatrice, Roncagalli, Romain, Vié, Henri, Malissen, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789201/
https://www.ncbi.nlm.nih.gov/pubmed/35061003
http://dx.doi.org/10.1084/jem.20211295
Descripción
Sumario:We exploited traceable gene tagging in primary human T cells to establish the composition and dynamics of seven canonical TCR-induced protein signaling complexes (signalosomes) using affinity purification coupled with mass spectrometry (AP-MS). It unveiled how the LAT adaptor assembles higher-order molecular condensates and revealed that the proximal TCR-signaling network has a high degree of qualitative and quantitative conservation between human CD4(+) and CD8(+) T cells. Such systems-level conservation also extended across human and mouse T cells and unexpectedly encompassed protein–protein interaction stoichiometry. Independently of evolutionary considerations, our study suggests that a drug targeting the proximal TCR signaling network should behave similarly when applied to human and mouse T cells. However, considering that signaling differences likely exist between the distal TCR-signaling pathway of human and mouse, our fast-track AP-MS approach should be favored to determine the mechanism of action of drugs targeting human T cell activation. An opportunity is illustrated here using an inhibitor of the LCK protein tyrosine kinase as a proof-of-concept.